| abstract |
A stable solid form of (S) -4-amino-N- (1- (4-chlorophenyl) useful for the treatment or prevention of a disease or pathological condition mediated by protenkinase B (AKT). Acquisition of -3-hydroxypropyl) -1- (7H-pyrrolo [2,3-d] -pyrimidin-4-yl) piperidine-4-carboxamide. The compound of crystalline form B having a specific X-ray powder diffraction pattern, a method of preparing the crystalline form. A method in which there are crystalline forms A, B and C of the compound, and the compound of the form A or C is stirred in a slurry state in acetone or acetonitonyl, particularly acetonitrile, and converted to form B, followed by filtration and drying. . The period of time may depend on the temperature of the slurry, and if the slurry is 50 ° C., the process yields an acceptable conversion yield if the compound is stirred for at least 3 days. Pharmaceutical compositions containing them and the use of such forms in therapy. [Selection] Figure 3.2 |